Shareholders Equity (Quarterly) Chart

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2020. Start Trial.
Date Value
September 30, 2026 356.97M
June 30, 2026 387.27M
March 31, 2026 211.94M
December 31, 2025 246.94M
September 30, 2025 218.99M
June 30, 2025 248.73M
March 31, 2025 55.06M
December 31, 2024 71.52M
September 30, 2024 88.80M
June 30, 2024 108.87M
March 31, 2024 53.85M
December 31, 2023 74.94M
September 30, 2023 -49.11M
Date Value
June 30, 2023 -37.11M
March 31, 2023 -14.95M
December 31, 2022 0.949M
September 30, 2022 11.13M
June 30, 2022 32.71M
March 31, 2022 50.72M
December 31, 2021 95.38M
September 30, 2021 140.39M
June 30, 2021 186.50M
March 31, 2021 222.87M
December 31, 2020 251.30M
September 30, 2020 267.64M
June 30, 2020 -26.79M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Imunon, Inc. 2.622M
Altimmune, Inc. 443.57M
Agenus, Inc. -105.37M
Amgen, Inc. 14.35B
Anika Therapeutics, Inc. 137.58M

Shareholders Equity (Quarterly) Related Metrics